Welcome to our dedicated page for Cibus SEC filings (Ticker: CBUS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cibus, Inc.'s SEC filings document an agricultural biotechnology company that uses proprietary gene-editing technologies to develop plant traits for licensing to seed companies. The filings describe its royalty-oriented model, productivity traits for major agricultural food crops, and trait categories tied to weeds, pests, diseases, sustainability and yield challenges.
The company's regulatory record includes 8-K material-event reports, financial-results exhibits, proxy materials, governance disclosures and capital-structure information for its Class A common stock. These filings also cover board appointments, compensatory arrangements, shareholder voting matters, material agreements, registered securities and business disclosures related to the development and commercialization of gene-edited crop traits.
Cibus, Inc. submitted a current report describing that it has announced its financial results for the three months ended June 30, 2025 and provided a year-to-date business update. These results and the business update are contained in a press release dated August 14, 2025, which is furnished as Exhibit 99.1.
The company clarifies that this press release is being furnished, not filed, so it is not automatically subject to certain Exchange Act liabilities or incorporated into other securities law filings unless specifically referenced. The report is signed on behalf of Cibus by Interim Chief Executive Officer Peter Beetham.